News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Fully equipped labs with 75-member team set-up and made operational in <100 days
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Science communication brings behavioural changes
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
To enable company to be future-ready by tapping potential in CDMO space
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
The company is addressing these observations
Subscribe To Our Newsletter & Stay Updated
